Home / Expertise / Intellectual Property
cut away of nautilus shell showing the beautiful spiral inside

Intellectual Property

International

In today’s knowledge economy, a large part of the value of your business is based on intangible assets and goodwill. Your intellectual property plays a key role in obtaining a competitive advantage. A cohesive IP strategy, including both commercialisation and enforcement, will ensure you get maximum value from your portfolio. With 150 specialist lawyers in 33 countries, we understand your business needs and have worked with some of the best-known brands, from banks to tech and media companies, pharmaceuticals and FMCG companies. This industry-specific approach can help you realise your commercial goals.

The right brands will win the hearts and minds of your customers. The right patents will prevent others exploiting your ideas or provide a substantial barrier to market access. Copyright, know-how and designs also play a vital role. We focus on key sectors relevant to you such as lifesciences, automotive, machinery, manufacturing, consumer products, financial services and TMC. This means you get in-depth industry knowledge as well as legal expertise for the protection of your IP. If you are involved in a dispute, we can guide you through the litigation process.

Read more Read less
June 2019
CMS In­tel­lec­tu­al Prop­erty Glob­al Bro­chure
In today’s know­ledge eco­nomy, a large part of the value of your busi­ness de­pends on in­tan­gible as­sets and good­will. Your in­tel­lec­tu­al prop­erty (IP) plays a key role in gain­ing and keep­ing your com­pet­it­ive edge.
Our In­ter­na­tion­al In­tel­lec­tu­al Prop­erty Group
In­tel­lec­tu­al Prop­erty (IP) rep­res­ents one of the most im­port­ant re­sources a com­pany can have, and CMS helps cli­ents to se­cure and pro­tect such stra­tegic as­sets. CMS has more than 150 at­tor­neys who spe­cial­ise in this area and are mem­bers of the rel­eva
CMS Ex­pert Guides
Easy ac­cess to ex­pert ad­vice that’s rel­ev­ant to you

Feed

Show only
31 July 2020
An­nu­al Re­view 2019 – 2020
We are liv­ing in tur­bu­lent times, char­ac­ter­ised by polit­ic­al, cli­mate and health crises. The most acute of these – the COV­ID-19 pan­dem­ic – has clearly shown how in­ter­con­nec­ted our eco­nom­ies are: travel, com­merce and sup­ply chains world­wide have been im­pacted. No in­di­vidu­al or busi­ness has re­mained totally un­af­fected by it.As a glob­al or­gan­isa­tion, with a pres­ence in key busi­ness hubs around the world, we are wit­ness­ing the im­pact of the pan­dem­ic firsthand. Our teams in Asia, Europe, Africa and Lat­in Amer­ica are help­ing cli­ents deal with this un­pre­ced­en­ted situ­ation. Un­fold­ing in dif­fer­ent in­tens­it­ies in dif­fer­ent parts of the world at dif­fer­ent times, our teams are in the for­tu­nate po­s­i­tion of be­ing able to con­nect with and learn from each oth­er. This en­ables us to sup­port our cli­ents in a mean­ing­ful way, listen­ing to and un­der­stand­ing their con­cerns and provid­ing them with busi­ness-rel­ev­ant ad­vice that draws on in­sights from our ex­perts world­wide.In this crisis, we, as a so­ci­ety, are at a cross­roads. What is cer­tain is that for in­di­vidu­als and busi­nesses (ours in­cluded) there will be no ‘back to busi­ness as usu­al’. Things need to (and will) change. How we shape the ‘new nor­mal’ is up to us. In this An­nu­al Re­view, we look at some key de­vel­op­ments that are in­creas­ingly im­pact­ing busi­ness suc­cess. Com­pan­ies need to take these in­to con­sid­er­a­tion when ad­apt­ing their op­er­a­tions to the new busi­ness en­vir­on­ment.The months ahead will be chal­len­ging for us all. Busi­nesses will need to think stra­tegic­ally and po­s­i­tion them­selves for suc­cess in the new nor­mal. We at CMS see it as our task to guide our cli­ents through this chan­ging busi­ness land­scape.Mat­thi­as Licht­blau (Ex­ec­ut­ive Dir­ect­or) Pierre-Sé­bas­tien Thill (Chair­man) Duncan We­st­on (Ex­ec­ut­ive Part­ner) CMS Ex­ec­ut­ive Team
08 July 2020
“WIPO PROOF”: WIPO’s new on­line ser­vice which helps in­nov­at­ors and cre­at­ors...
The World In­tel­lec­tu­al Prop­erty Or­gan­isa­tion (WIPO) re­cently launched its new on­line busi­ness ser­vice, “WIPO PROOF”. The plat­form aims to help in­nov­at­ors and cre­at­ors safe­guard their in­tel­lec­tu­al...
31 August 2019
Con­sumer Products News­let­ter
In­tel­lec­tu­al Prop­erty and Un­fair Com­pet­i­tion law
26 May 2020
European Pat­ent Of­fice COV­ID-19 pro­vi­sions - as at 25 May 2020
The EPO has re­cently is­sued fur­ther in­form­a­tion re­gard­ing or­al pro­ceed­ings be­fore ex­am­in­a­tion and op­pos­i­tion di­vi­sions and be­fore the Boards of Ap­peal. This art­icle sum­mar­ises all of the EPO’s COV­ID-19...
August 2019
How block­chain will re­volu­tion­ise the gam­ing in­dustry
26 May 2020
European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
August 2019
Game­play on-the-move
What's next for mo­bile es­ports?
05 May 2020
European Pat­ent Of­fice (EPO) COV­ID-19 pro­vi­sions – as at 5 May 2020
The EPO has now is­sued a fur­ther guid­ance no­tice re­gard­ing its dead­lines in light of the on­go­ing coronavir­us situ­ation, which re­places the pre­vi­ous no­tice dated 16 April 2020 and which will be pub­lished...
August 2019
Avoid­ing ugly head­lines
Com­pli­ance in es­ports
30 April 2020
COV­ID-19 - EUIPO ex­tends dead­lines
The EUIPO yes­ter­day ex­ten­ded time lim­its which are due to ex­pire between Fri­day, 1 May 2020 and Sunday, 17 May 2020 to Monday, 18 May 2020. This fol­lows the earli­er ex­ten­sion of time lim­its un­til 1 May...
19 August 2019
Will fans pay per view for ex­clus­ive es­ports con­tent?
27 March 2020
Man­aging clin­ic­al tri­als un­der COV­ID-19: New EU guid­ance is­sued for spon­sors...
The COV­ID-19 pan­dem­ic has had a dra­mat­ic im­pact on European health sys­tems, whose pri­or­ity first and fore­most is the treat­ment of pa­tients suf­fer­ing from this dis­ease both in the in-pa­tient and out-pa­tient...